Rana Fathy Hilal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rana Fathy Hilal has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
N. S. Zaki
Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt
3 shared publicationsR. M. Essam
Student Hospital, Cairo, Egypt
3 shared publications- Amira Elbendary
Department of Dermatology, Kasr Al Ainy Teaching Hospital Cairo University Cairo Egypt
2 shared publications Eman Shaarawy
2 shared publications- Noha A. Nagui
Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications Samia Esmat
Department of Dermatology, Kasr al Ainy Teaching Hospital, Cairo University, Cairo, Egypt
2 shared publications
Latest Publications
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2323-2333
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial
Background: Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment. Objectives: Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids. Methods: This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels. Results: A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide. Conclusion: Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2323-2333
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial
Background: Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment. Objectives: Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids. Methods: This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels. Results: A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide. Conclusion: Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image
- 17 March 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (2) , e70080
Pulsed Dye Laser Versus Carboxytherapy for the Treatment of Stria Rubra: A Randomized Clinical and Histopathological Study
Background: Pulsed Dye Laser (PDL) and carboxytherapy target the vascular component of Stria Rubra (SR), followed by a secondary rejuvenating effect. Objective: To compare the efficacy and safety of PDL and carboxytherapy for the treatment of SR. Materials & Methods: Twenty patients with SR were included in this study. Each patient received PDL to one randomly selected SR side and carboxytherapy to the other randomly selected SR side. Clinical outcome assessment was done using number of striae and maximum stria width, Vancouver Scar scale (VSS), Erythema index (EI), and histopathological evaluation. Results: Significant improvement in VSS, EI, and histopathological scoring was found after treatment with each modality, whether PDL or carboxytherapy. Comparison between both modalities revealed a non‐significant difference between PDL and carboxytherapy as regards VSS, EI, and histopathological scoring change. Histopathological analysis showed a significant increase of collagen and elastic fibres following PDL. Collagen fibres and perpendicular blood vessels increased significantly with carboxytherapy. PIH was encountered following PDL. Conclusion: Both PDL and carboxytherapy are effective for the treatment of SR. PDL is proposed to produce a better outcome as regards improving the texture of SR skin. The risk of pigmentation can be avoided by proper PDL dosage.
- 17 March 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (2) , e70080
Pulsed Dye Laser Versus Carboxytherapy for the Treatment of Stria Rubra: A Randomized Clinical and Histopathological Study
Background: Pulsed Dye Laser (PDL) and carboxytherapy target the vascular component of Stria Rubra (SR), followed by a secondary rejuvenating effect. Objective: To compare the efficacy and safety of PDL and carboxytherapy for the treatment of SR. Materials & Methods: Twenty patients with SR were included in this study. Each patient received PDL to one randomly selected SR side and carboxytherapy to the other randomly selected SR side. Clinical outcome assessment was done using number of striae and maximum stria width, Vancouver Scar scale (VSS), Erythema index (EI), and histopathological evaluation. Results: Significant improvement in VSS, EI, and histopathological scoring was found after treatment with each modality, whether PDL or carboxytherapy. Comparison between both modalities revealed a non‐significant difference between PDL and carboxytherapy as regards VSS, EI, and histopathological scoring change. Histopathological analysis showed a significant increase of collagen and elastic fibres following PDL. Collagen fibres and perpendicular blood vessels increased significantly with carboxytherapy. PIH was encountered following PDL. Conclusion: Both PDL and carboxytherapy are effective for the treatment of SR. PDL is proposed to produce a better outcome as regards improving the texture of SR skin. The risk of pigmentation can be avoided by proper PDL dosage.
- 8 September 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (3) , 253-259
Fractional CO2 Versus Radiofrequency as Hair Regrowth Enhancers for Female Androgenic Alopecia: A Randomized Controlled Trial
BACKGROUND: Androgenic alopecia (AGA) is a cosmetically disfiguring condition, which accounts for most cases of diffuse hair loss among females, negatively impacting their quality of life. Combining Fractional CO 2 (FCO 2 ) or Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil 5% could achieve a better clinical outcome. OBJECTIVE: To compare efficacy and safety of FCO 2 and FMRF, combined with minoxidil, for the treatment of female AGA. METHODS: Thirty patients with female AGA were randomly assigned to 2 groups (simple computerized randomization). Group A patients received FCO 2 to 1 randomly selected side of the scalp, and Group B patients received FMRF to 1 randomly selected side of the scalp (picking masked labeled cards). Patients received minoxidil 5%. RESULTS: Significant increase in trichoscopic hair counts and density was found after treatment with each modality whether minoxidil 5% alone, minoxidil combined with FCO 2 , or minoxidil combined with FMRF. A significantly greater increase in trichoscopic hair counts and density followed the treatment with minoxidil + FMRF, compared to either minoxidil + FCO 2 or minoxidil alone. CONCLUSION: It can be proposed that combining FMRF with minoxidil for the treatment of female AGA could be associated with higher efficacy and tolerability, compared to the other treatment modalities.
- 8 September 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (3) , 253-259
Fractional CO2 Versus Radiofrequency as Hair Regrowth Enhancers for Female Androgenic Alopecia: A Randomized Controlled Trial
BACKGROUND: Androgenic alopecia (AGA) is a cosmetically disfiguring condition, which accounts for most cases of diffuse hair loss among females, negatively impacting their quality of life. Combining Fractional CO 2 (FCO 2 ) or Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil 5% could achieve a better clinical outcome. OBJECTIVE: To compare efficacy and safety of FCO 2 and FMRF, combined with minoxidil, for the treatment of female AGA. METHODS: Thirty patients with female AGA were randomly assigned to 2 groups (simple computerized randomization). Group A patients received FCO 2 to 1 randomly selected side of the scalp, and Group B patients received FMRF to 1 randomly selected side of the scalp (picking masked labeled cards). Patients received minoxidil 5%. RESULTS: Significant increase in trichoscopic hair counts and density was found after treatment with each modality whether minoxidil 5% alone, minoxidil combined with FCO 2 , or minoxidil combined with FMRF. A significantly greater increase in trichoscopic hair counts and density followed the treatment with minoxidil + FMRF, compared to either minoxidil + FCO 2 or minoxidil alone. CONCLUSION: It can be proposed that combining FMRF with minoxidil for the treatment of female AGA could be associated with higher efficacy and tolerability, compared to the other treatment modalities.
- Open Access
- 30 November 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (5) , 1-8
Detection of IL-17A and IL-17F gene polymorphism in recurrent and disseminated pityriasis versicolor: a case-control study
Recurrent and disseminated pityriasis versicolor (RDPV) is a common clinical entity, characterized by its recurrent and disfiguring nature. Studies demonstrated host genetic variations in the immune response, especially the role of IL-17 in antifungal immunity. This study aimed to detect whether IL-17A and F gene polymorphisms are found in cases of RDPV. It included 100 cases of RDPV and 100 age and sex matched controls, from which EDTA blood samples were taken for single-nucleotide polymorphism analysis. IL-17A (rs2275913) and F (rs763780) were associated with a significantly increased incidence of developing RDPV. IL-17A and F gene polymorphism could be implicated as a risk factor for the development of RDPV.
- 30 November 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (5) , 1-8
Open AccessDetection of IL-17A and IL-17F gene polymorphism in recurrent and disseminated pityriasis versicolor: a case-control study
Recurrent and disseminated pityriasis versicolor (RDPV) is a common clinical entity, characterized by its recurrent and disfiguring nature. Studies demonstrated host genetic variations in the immune response, especially the role of IL-17 in antifungal immunity. This study aimed to detect whether IL-17A and F gene polymorphisms are found in cases of RDPV. It included 100 cases of RDPV and 100 age and sex matched controls, from which EDTA blood samples were taken for single-nucleotide polymorphism analysis. IL-17A (rs2275913) and F (rs763780) were associated with a significantly increased incidence of developing RDPV. IL-17A and F gene polymorphism could be implicated as a risk factor for the development of RDPV.
- 1 March 2022
- Published by Elsevier in Clinics in Dermatology
- Vol. 40 (2) , 198-205
How far is vitamin D implicated in cutaneous infections
- 1 March 2022
- Published by Elsevier in Clinics in Dermatology
- Vol. 40 (2) , 198-205
How far is vitamin D implicated in cutaneous infections
- 24 August 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (11) , 1480-1485
Automated Microneedling Versus Fractional CO2 Laser in Treatment of Traumatic Scars: A Clinical and Histochemical Study
BACKGROUND/OBJECTIVES: Microneedling has shown satisfactory effects in scar rejuvenation. Comparisons of its results with fractional laser are limited. This study aims to compare the efficacy and safety of automated microneedling versus fractional carbon dioxide (CO2) laser in treatment of traumatic scars on clinical and histochemical bases. MATERIALS AND METHODS: Thirty patients with traumatic facial scars were randomized to treatment with 4 monthly sessions of either automated microneedling or fractional CO2 laser. Assessment of scars was performed at baseline and 3 months after the last treatment session, clinically by the modified Vancouver Scar Scale (mVSS) and histochemically by quantitative assessment of collagen and elastic fibers. RESULTS: Both groups showed improvement in mVSS, collagen, and elastin contents after treatment. Percentage improvement of collagen and elastin content was higher after treatment by a laser compared with microneedling, in case of the collagen content. Percentage increase in the collagen content after treatment was higher in atrophic scars of the laser group than those of the microneedling group. CONCLUSION: In this small study, microneedling was as safe as fractional CO2 laser for rejuvenation of traumatic scars with comparable clinical effects. Fractional CO2 laser is more powerful in stimulating neocollagenesis. Automated microneedling is effective for treatment of hypertrophic scars.
- 24 August 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 47 (11) , 1480-1485
Automated Microneedling Versus Fractional CO2 Laser in Treatment of Traumatic Scars: A Clinical and Histochemical Study
BACKGROUND/OBJECTIVES: Microneedling has shown satisfactory effects in scar rejuvenation. Comparisons of its results with fractional laser are limited. This study aims to compare the efficacy and safety of automated microneedling versus fractional carbon dioxide (CO2) laser in treatment of traumatic scars on clinical and histochemical bases. MATERIALS AND METHODS: Thirty patients with traumatic facial scars were randomized to treatment with 4 monthly sessions of either automated microneedling or fractional CO2 laser. Assessment of scars was performed at baseline and 3 months after the last treatment session, clinically by the modified Vancouver Scar Scale (mVSS) and histochemically by quantitative assessment of collagen and elastic fibers. RESULTS: Both groups showed improvement in mVSS, collagen, and elastin contents after treatment. Percentage improvement of collagen and elastin content was higher after treatment by a laser compared with microneedling, in case of the collagen content. Percentage increase in the collagen content after treatment was higher in atrophic scars of the laser group than those of the microneedling group. CONCLUSION: In this small study, microneedling was as safe as fractional CO2 laser for rejuvenation of traumatic scars with comparable clinical effects. Fractional CO2 laser is more powerful in stimulating neocollagenesis. Automated microneedling is effective for treatment of hypertrophic scars.
- 23 June 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (10) , 1325-1340
Combining Low Power Fractional CO2 With QS‐NdYAG Toning in the Treatment of Melasma Reduces the Incidence of Punctate Leukoderma
Background and Objectives: Q‐switched Nd:YAG (QS‐Nd:YAG) toning (low fluence, large spot size, and high frequency) has been used successfully for the treatment of melasma, especially in dark skin phototypes. Punctate leukoderma was found to be a frequent complication that reduced the safety of this procedure. Combining low power fractional CO2 laser, which is another effective melasma laser therapy, might improve the efficacy and safety of this procedure. The aim of this study was to evaluate the effect of combining low power fractional CO2 laser with QS‐Nd:YAG toning in the treatment of melasma.Study Design/Materials and Methods: A randomized comparative split‐face study included a total of 30 patients with bilateral, symmetrical melasma. All patients received QS‐Nd:YAG toning on one randomly selected side of the face, while the other side randomly received either low power fractional CO2 alone (group A) or combined QS‐Nd:YAG toning with low power fractional CO2 (group B). QS‐Nd:YAG toning sessions were scheduled every two weeks for nine consecutive sessions, and low power fractional CO2 sessions were received every 4 weeks for three consecutive sessions. The assessment was done using the modified melasma area and severity index (mMASI) score, spectrophotometry (melanin index [MI] and erythema index [EI]), photography, blinded physician assessment, and patient satisfaction (at baseline, 1 week and 8‐12 weeks after the last treatment sessions).Results: A significant reduction in the mMASI score and MI was obtained with all treatment regimens. On comparing different modalities, group A reduction in mMASI and MI was significantly greater on the side receiving QS‐ND:YAG toning (64.03% and 8.27%, respectively), than the side receiving low power fractional CO2 laser alone (36.02%. 2.64%, respectively). On the other hand, reduction of mMASI score and MI showed no statistical significance between the side receiving QS‐Nd:YAG toning alone and the combined modality. Punctate leukoderma occurred in four cases (13%) on the side receiving QS‐Nd:YAG toning.Conclusion: QS‐Nd:YAG toning is significantly more effective than low power fractional CO2 in the treatment of melasma when used separately. Although combining low power fractional CO2 with QS‐Nd:YAG toning does not increase its efficacy, it minimizes the incidence of the undesirable punctate leukoderma complication and achieves lower recurrence. This combination can thus be recommended as a safe and effective measure for the treatment of melasma. © 2021 Wiley Periodicals LLC.
- 23 June 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (10) , 1325-1340
Combining Low Power Fractional CO2 With QS‐NdYAG Toning in the Treatment of Melasma Reduces the Incidence of Punctate Leukoderma
Background and Objectives: Q‐switched Nd:YAG (QS‐Nd:YAG) toning (low fluence, large spot size, and high frequency) has been used successfully for the treatment of melasma, especially in dark skin phototypes. Punctate leukoderma was found to be a frequent complication that reduced the safety of this procedure. Combining low power fractional CO2 laser, which is another effective melasma laser therapy, might improve the efficacy and safety of this procedure. The aim of this study was to evaluate the effect of combining low power fractional CO2 laser with QS‐Nd:YAG toning in the treatment of melasma.Study Design/Materials and Methods: A randomized comparative split‐face study included a total of 30 patients with bilateral, symmetrical melasma. All patients received QS‐Nd:YAG toning on one randomly selected side of the face, while the other side randomly received either low power fractional CO2 alone (group A) or combined QS‐Nd:YAG toning with low power fractional CO2 (group B). QS‐Nd:YAG toning sessions were scheduled every two weeks for nine consecutive sessions, and low power fractional CO2 sessions were received every 4 weeks for three consecutive sessions. The assessment was done using the modified melasma area and severity index (mMASI) score, spectrophotometry (melanin index [MI] and erythema index [EI]), photography, blinded physician assessment, and patient satisfaction (at baseline, 1 week and 8‐12 weeks after the last treatment sessions).Results: A significant reduction in the mMASI score and MI was obtained with all treatment regimens. On comparing different modalities, group A reduction in mMASI and MI was significantly greater on the side receiving QS‐ND:YAG toning (64.03% and 8.27%, respectively), than the side receiving low power fractional CO2 laser alone (36.02%. 2.64%, respectively). On the other hand, reduction of mMASI score and MI showed no statistical significance between the side receiving QS‐Nd:YAG toning alone and the combined modality. Punctate leukoderma occurred in four cases (13%) on the side receiving QS‐Nd:YAG toning.Conclusion: QS‐Nd:YAG toning is significantly more effective than low power fractional CO2 in the treatment of melasma when used separately. Although combining low power fractional CO2 with QS‐Nd:YAG toning does not increase its efficacy, it minimizes the incidence of the undesirable punctate leukoderma complication and achieves lower recurrence. This combination can thus be recommended as a safe and effective measure for the treatment of melasma. © 2021 Wiley Periodicals LLC.
- 19 March 2021
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 314 (2) , 167-182
Comparative study for treatment of alopecia areata using carboxy therapy, intralesional corticosteroids, and a combination of both
Alopecia Areata (AA) is a common autoimmune disease, with an unpredictable course and no standard treatment with guaranteed outcome. Intralesional corticosteroids is the most commonly used treatment for patchy AA, but with a common side effect of localized atrophy. Thirty patients with localized AA, with three patches were included in this study. Each alopecic patch in each patient was subjected to treatment by intralesional carbon dioxide injection (carboxy therapy), intralesional corticosteroids (ILC) and a combination of both. Sessions were done every 2 weeks for a total of 12 weeks, followed by a 2-month follow-up period. Evaluation was done at baseline, after treatment and after follow-up, clinically by modified SALT score (a novel modification of the SALT score), dermoscopically (yellow dots, black dots, tapered hair, regrowing hair) and by photography. All treatment regimens resulted in significant improvement of mSALT score and dermoscopic parameters. Comparison of the three treatment modalities revealed a 79.2% hair regrowth following the combined regimen, 69.5% improvement after ILC, and 50% improvement after carboxy therapy, with a statistical difference. The combined regimen also produced the largest significant increase in regrowing hair after treatment. Side effects included temporary pain during injection and relapse in the alopecic patch treated by ILC in one patient. All treatment regimens proved effective for treatment of patchy alopecia areata, with highest efficacy encountered following the combined modality as it caused the greatest and earliest hair regrowth. Study registered in Protocol Registration and Results System (clincaltrials.gov). Registration number: NCT04228029
- 19 March 2021
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 314 (2) , 167-182
Comparative study for treatment of alopecia areata using carboxy therapy, intralesional corticosteroids, and a combination of both
Alopecia Areata (AA) is a common autoimmune disease, with an unpredictable course and no standard treatment with guaranteed outcome. Intralesional corticosteroids is the most commonly used treatment for patchy AA, but with a common side effect of localized atrophy. Thirty patients with localized AA, with three patches were included in this study. Each alopecic patch in each patient was subjected to treatment by intralesional carbon dioxide injection (carboxy therapy), intralesional corticosteroids (ILC) and a combination of both. Sessions were done every 2 weeks for a total of 12 weeks, followed by a 2-month follow-up period. Evaluation was done at baseline, after treatment and after follow-up, clinically by modified SALT score (a novel modification of the SALT score), dermoscopically (yellow dots, black dots, tapered hair, regrowing hair) and by photography. All treatment regimens resulted in significant improvement of mSALT score and dermoscopic parameters. Comparison of the three treatment modalities revealed a 79.2% hair regrowth following the combined regimen, 69.5% improvement after ILC, and 50% improvement after carboxy therapy, with a statistical difference. The combined regimen also produced the largest significant increase in regrowing hair after treatment. Side effects included temporary pain during injection and relapse in the alopecic patch treated by ILC in one patient. All treatment regimens proved effective for treatment of patchy alopecia areata, with highest efficacy encountered following the combined modality as it caused the greatest and earliest hair regrowth. Study registered in Protocol Registration and Results System (clincaltrials.gov). Registration number: NCT04228029
- 26 June 2020
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (3) , 324-332
Q‐Switched Nd:YAG (532 nm) Laser Versus Intra‐Dermal Tranexamic Acid for Treatment of Facial Ephelides: A Split Face, Randomized, Comparative Trial
Background and Objectives: To compare the efficacy and safety of intradermal injection of tranexamic acid (TXA) versus Q switched (QS) KTP (532 nm) in the treatment of facial ephelides.Study Design/Materials and Methods: A randomized comparative split‐face study included a total of 30 female patients with bilateral facial ephelides. One cheek was treated by intra‐dermal TXA injections and the other was treated by QS‐KTP (532 nm). Patient assessment was performed by photography, pigmentation area, severity index and spectrophotometry at baseline, 1 week after treatment, and 2 months after treatment.Results: A significant difference was found between both sides regarding the percentage change of pigmentation area, severity score (PSI) and melanin index (MI) after treatment and during follow up, favoring laser (P = 0.001). PSI decreased after treatment by 66.5% and 15.4% (laser and TXA sides respectively), further decrease after follow‐up was 69.4% with laser and 26.1% with TXA. MI improved by 3.7% after KTP laser to 7.7% after follow‐up and by 2.4% after TXA injections to 6.5% after follow‐up. Four patients developed post‐inflammatory hyperpigmentation following QS‐KTP.Conclusion: QS‐KTP laser is superior to intradermal TXA injection in the treatment of facial ephelides. Lasers Surg. Med. © 2020 Wiley Periodicals LLC
- 26 June 2020
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (3) , 324-332
Q‐Switched Nd:YAG (532 nm) Laser Versus Intra‐Dermal Tranexamic Acid for Treatment of Facial Ephelides: A Split Face, Randomized, Comparative Trial
Background and Objectives: To compare the efficacy and safety of intradermal injection of tranexamic acid (TXA) versus Q switched (QS) KTP (532 nm) in the treatment of facial ephelides.Study Design/Materials and Methods: A randomized comparative split‐face study included a total of 30 female patients with bilateral facial ephelides. One cheek was treated by intra‐dermal TXA injections and the other was treated by QS‐KTP (532 nm). Patient assessment was performed by photography, pigmentation area, severity index and spectrophotometry at baseline, 1 week after treatment, and 2 months after treatment.Results: A significant difference was found between both sides regarding the percentage change of pigmentation area, severity score (PSI) and melanin index (MI) after treatment and during follow up, favoring laser (P = 0.001). PSI decreased after treatment by 66.5% and 15.4% (laser and TXA sides respectively), further decrease after follow‐up was 69.4% with laser and 26.1% with TXA. MI improved by 3.7% after KTP laser to 7.7% after follow‐up and by 2.4% after TXA injections to 6.5% after follow‐up. Four patients developed post‐inflammatory hyperpigmentation following QS‐KTP.Conclusion: QS‐KTP laser is superior to intradermal TXA injection in the treatment of facial ephelides. Lasers Surg. Med. © 2020 Wiley Periodicals LLC